Pharma
Global Hepatitis Testing Market Opportunities and Forecast 2023-2030
  • DLR2934
  • 07 January, 2022
  • Pharma & Healthcare
  • Pages: 120
  • Global
Global Hepatitis Testing Market, By Disease Type (Hepatitis B, Hepatitis C, Other Hepatitis), By Technology (ELISA, RDT, PCR, INAAT), By End User (Hospitals, Diagnostic Laboratories, Blood Banks) and opportunities and forecast 2023-2030

Hepatitis Testing Market Overview

The growth of the global hepatitis testing market is being driven by factors like the high burden of hepatitis, increasing blood transfusion and donations, benefits of POC instruments and kits, and awareness initiatives on liver disease.

High cost of macromolecule tests, lack of mandates for nucleic acid tests in developing countries and unfavourable reimbursement scenarios are expected to restrain hepatitis market growth. rising markets, rising technological advancements in molecular diagnostics, and growth within the biotechnology and biopharmaceutical industries are expected to offer strong growth opportunities for players within the market.

Report Metric Details
Market size available for years 2019–2027
Base year considered 2019
Forecast period 2020–2027
Forecast unit Value (USD Million)
Segments covered Disease Type, Technology, End User and Region
Regions covered North America (the U.S. and Canada), Europe (UK, Germany, France, Italy, Spain, Russia, Rest of Europe), Asia-Pacific (China, India, Japan, Australia, South East Asia, Rest of Asia Pacific), Latin America and the Middle East and Africa (Brazil, Saudi Arabia, UAE, Rest of LAMEA)
Companies covered F. Hoffmann-La Roche Ltd., Abbott Laboratories, Siemens Healthineers AG, Bio-Rad Laboratories, Inc., Danaher Corporation, QIAGEN, bioMérieux SA, DiaSorin S.P.A., Ortho Clinical Diagnostics, MedMira Inc., Fujirebio US, Inc., Grifols, S.A.

The covid-19 Impact on Hepatitis Testing Market:

Like several different industries, COVID-19 badly knocked the electronic and semiconductor trade. This new event has compact nearly 230 countries in exactly a couple of weeks, leading to the forced conclusion of producing and transportation activities at intervals and across the countries. This has directly affected the expansion of the sector. It's calculable that COVID-19 to depart over USD thirty billion impacts on the physics and semiconductor trade. The arena is majorly affected thanks to transport restrictions on major physics and semiconductor staple suppliers. However, the rising want for semiconductors in many industries can supply fast market recovery over the longer-term amount.
 
Hepatitis Testing Market Segment Overview



By Disease Type, Hepatitis B segment is anticipated to dominate the market throughout the forecast amount.
Based on technology, the hepatitis testing market is segmented into enzyme-linked immunosorbent assay (ELISA), fast diagnostic tests, nucleic acid chain reaction (PCR), isothermal supermolecule amplification technology (INAAT), and other technologies (such as sequencing, mass spectroscopy, and western blotting). The spectrometry segment accounted for the largest share of the hepatitis testing market in 2020.

Based on user, the hospital & diagnostic laboratories phase accounted for the largest share of the hepatitis testing market.

Market Analysis, Insights and Forecast – By  Disease Type
·       Hepatitis B
·       Hepatitis C
·       Other Hepatitis

Market Analysis, Insights and Forecast – By Technology
·       ELISA
·       RDT
·       PCR
·       INAAT

Market Analysis, Insights and Forecast – By End User
·       Hospitals
·       Diagnostic Laboratories
·       Blood Banks

Hepatitis Testing Market Regional Overview

Region-wise, in terms of regions, North America dominates the global market, and this trend is predicted to continue throughout the forecast period. the large share and high growth of this region may be attributed to the rising prevalence of hepatitis and increased research and clinical trials for hepatitis testing within the US.

However, the Asia Pacific market is estimated to grow at the highest CAGR throughout the forecast period. High burden of hepatitis infections, rising disposable income levels, improving healthcare infrastructure, and increasing awareness of infectious disease testing are the major factors driving the growth of the hepatitis testing market in the Asia Pacific.

Hepatitis Testing Market, By Geography

·       North America (US & Canada)
·       Europe (UK, Germany, France, Italy, Spain, & Rest of Europe)
·       Asia-Pacific (Japan, China, India, Australia, & South Korea, & Rest of Asia-Pacific)
·       LAMEA (Brazil, Saudi Arabia, UAE & Rest of LAMEA)
 
Hepatitis Testing Market Competitor overview

Some key developments and strategies adopted by manufacturers in the Hepatitis Testing are highlighted below.
 
·       In 2020, Hanwha Chemical merged with Hanwha Q CELLS and Advanced Materials and got renamed as Hanwha Solution.

Hepatitis Testing  Market, Key Players

·       F.Hoffmann-La Roche Ltd.
·       Abbott Laboratories
·       Siemens Healthineers AG
·       Bio-Rad Laboratories, Inc.
·       Danaher Corporation
·       QIAGEN
·       bioMérieux SA
·       DiaSorin S.P.A.
·       Ortho Clinical Diagnostics
·       MedMira Inc.
·       Fujirebio US, Inc.
·       Grifols, S.A.


 

Frequently Asked Questions (FAQ) :

Q1. What is the total CAGR expected to be recorded for the Hepatitis Testing market during the forecast period?

A. Hepatitis Testing market is expected to record a CAGR of ~ xx% during the forecast period.

Q2. Which segment is projected to hold the largest share in the Hepatitis Testing Market?

A. Hepatitis B segment is projected to hold the largest share in the Hepatitis Testing Market.

Q3. What are the driving factors for the Hepatitis Testing market?

A. the high burden of hepatitis, increasing blood transfusion and donations, benefits of POC instruments and kits is key factors that boost the growth of the Hepatitis Testing market progressively.

Q4. Which Segments are covered in the Hepatitis Testing market report?

A. Disease Type , Technology and Application, and Region, these segments are covered in the Hepatitis Testing market report.

Q5. Which are the prominent players offering Hepatitis Testing ?

A. F.Hoffmann-La Roche Ltd. , Abbott Laboratories, Siemens Healthineers AG , Bio-Rad Laboratories, Inc. , Danaher Corporation , QIAGEN , bioMérieux SA , DiaSorin S.P.A., Ortho Clinical Diagnostics, MedMira Inc., Fujirebio US, Inc. , Grifols, S.A. ,.
Hepatitis Testing Market Study Global Market Analysis, Insights and Forecast, 2020-2027

    1. Introduction

    • 1.1. Research Scope
    • 1.2. Market Segmentation
    • 1.3. Research Methodology
    • 1.4. Definitions and Assumptions

    2. Executive Summary

      3. Market Dynamics

      • 3.1. Market Drivers
      • 3.2. Market Restraints
      • 3.3. Market Opportunities

      4. Key Insights

      • 4.1. Key Emerging Trends – For Major Countries
      • 4.2. Latest Technological Advancement
      • 4.3. Regulatory Landscape
      • 4.4. Industry SWOT Analysis
      • 4.5. Porters Five Forces Analysis

      5. Global Hepatitis Testing Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 5.1. Key Findings / Summary
      • 5.2. Market Analysis, Insights and Forecast – By Disease Type
        • 5.2.1. Hepatitis B
        • 5.2.2. Hepatitis C
        • 5.2.3. Other Hepatitis
      • 5.3. Market Analysis, Insights and Forecast – By Technology
        • 5.3.1. ELISA
        • 5.3.2. RDT
        • 5.3.3. PCR
        • 5.3.4. INAAT
      • 5.4. Market Analysis, Insights and Forecast – By End User
        • 5.4.1. Hospitals
        • 5.4.2. Diagnostic Laboratories
        • 5.4.3. Blood Banks
      • 5.5. Market Analysis, Insights and Forecast – By Region
        • 5.5.1. North America
        • 5.5.2. Europe
        • 5.5.3. Asia Pacific
        • 5.5.4. Latin America, Middle East, and Africa

      6. North America Hepatitis Testing Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 6.1. Key Findings / Summary
      • 6.2. Market Analysis, Insights and Forecast – By Disease Type
        • 6.2.1. Hepatitis B
        • 6.2.2. Hepatitis C
        • 6.2.3. Other Hepatitis
      • 6.3. Market Analysis, Insights and Forecast – By Technology
        • 6.3.1. ELISA
        • 6.3.2. RDT
        • 6.3.3. PCR
        • 6.3.4. INAAT
      • 6.4. Market Analysis, Insights and Forecast – By End User
        • 6.4.1. Hospitals
        • 6.4.2. Diagnostic Laboratories
        • 6.4.3. Blood Banks
      • 6.5. Market Analysis, Insights and Forecast – By Country
        • 6.5.1. U.S.
        • 6.5.2. Canada

      7. Europe Hepatitis Testing Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 7.1. Key Findings / Summary
      • 7.2. Market Analysis, Insights and Forecast – By Disease Type
        • 7.2.1. Hepatitis B
        • 7.2.2. Hepatitis C
        • 7.2.3. Other Hepatitis
      • 7.3. Market Analysis, Insights and Forecast – By Technology
        • 7.3.1. ELISA
        • 7.3.2. RDT
        • 7.3.3. PCR
        • 7.3.4. INAAT
      • 7.4. Market Analysis, Insights and Forecast – By End User
        • 7.4.1. Hospitals
        • 7.4.2. Diagnostic Laboratories
        • 7.4.3. Blood Banks
      • 7.5. Market Analysis, Insights and Forecast – By Country
        • 7.5.1. UK
        • 7.5.2. Germany
        • 7.5.3. France
        • 7.5.4. Italy
        • 7.5.5. Spain
        • 7.5.6. Russia
        • 7.5.7. Rest of Europe

      8. Asia Pacific Hepatitis Testing Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 8.1. Key Findings / Summary
      • 8.2. Market Analysis, Insights and Forecast – By Disease Type
        • 8.2.1. Hepatitis B
        • 8.2.2. Hepatitis C
        • 8.2.3. Other Hepatitis
      • 8.3. Market Analysis, Insights and Forecast – By Technology
        • 8.3.1. ELISA
        • 8.3.2. RDT
        • 8.3.3. PCR
        • 8.3.4. INAAT
      • 8.4. Market Analysis, Insights and Forecast – By End User
        • 8.4.1. Hospitals
        • 8.4.2. Diagnostic Laboratories
        • 8.4.3. Blood Banks
      • 8.5. Market Analysis, Insights and Forecast – By Country
        • 8.5.1. China
        • 8.5.2. India
        • 8.5.3. Japan
        • 8.5.4. Australia
        • 8.5.5. South East Asia
        • 8.5.6. Rest of Asia Pacific

      9. Latin America, Middle East, and Africa Hepatitis Testing Market Analysis (USD Billion), Insights and Forecast, 2020-2027

      • 9.1. Key Findings / Summary
      • 9.2. Market Analysis, Insights and Forecast – By Disease Type
        • 9.2.1. Hepatitis B
        • 9.2.2. Hepatitis C
        • 9.2.3. Other Hepatitis
      • 9.3. Market Analysis, Insights and Forecast – By Technology
        • 9.3.1. ELISA
        • 9.3.2. RDT
        • 9.3.3. PCR
        • 9.3.4. INAAT
      • 9.4. Market Analysis, Insights and Forecast – By End User
        • 9.4.1. Hospitals
        • 9.4.2. Diagnostic Laboratories
        • 9.4.3. Blood Banks
      • 9.5. Market Analysis, Insights and Forecast – By Country
        • 9.5.1. Brazil
        • 9.5.2. Saudi Arabia
        • 9.5.3. UAE
        • 9.5.4. Rest of LAMEA

      10. Competitive Analysis

      • 10.1. Company Market Share Analysis, 2018
      • 10.2. Key Industry Developments
      • 10.3. Company Profile
      • 10.4. F.Hoffmann-La Roche Ltd.
        • 10.4.1. Business Overview
        • 10.4.2. Segment 1 & Service Offering
        • 10.4.3. Overall Revenue
        • 10.4.4. Geographic Presence
        • 10.4.5. Recent Development
      *Similar details will be provided for the following companies
      • 10.5. Abbott Laboratories
      • 10.6. Siemens Healthineers AG
      • 10.7. Bio-Rad Laboratories, Inc.
      • 10.8. Danaher Corporation
      • 10.9. QIAGEN
      • 10.10. bioMérieux SA
      • 10.11. DiaSorin S.P.A
      • 10.12. Ortho Clinical Diagnostics
      • 10.13. MedMira Inc.
      • 10.14. Fujirebio US, Inc.

      Report You Might be Interested

      Choose License Type

      • USD
      • GBP
      • EURO
      • INR
      Credit card Logo

      Happy To Assist You

      Have a Question? email us at

      [email protected]

      Or Call Us On

      US +1 360 851 1343

      IND +91 880 579 4934